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The histologic presence of benign dermal nevus cells in contiguity with primary cutaneous melanoma, as a distinct
population separate from malignant melanocytes, was evaluated in a large referral data base. The melanomas were limited to
superficial spreading melanoma (SSM) and nodular melanoma (NM). Overall, dermal melanocytic nevi were found
associated with 1126 of 1954 primary SSM/NM (57.6%). When the melanomas were stratified by tumor thickness, an inverse
relationship between the presence of benign nevus cells and tumor thickness was found: 64.9% of tumors less than 0.76mm
and 64.5% of those between 0.76 and 1.69mm were associated with dermal nevi, whereas in the thickness range
1.70–3.60mm, there were 45.6% associated nevi, and in melanomas greater than 3.60mm, there were only 32.0% noted to
have nevus cells. When melanomas were separated by nevus type, it was found that 41% were associated with an acquired
pattern nevus, 38% with congenital pattern nevus, and 21% with dysplastic nevus. It may be concluded that 1) the histologic
presence of nevus cells is a common event in SSM/NM; 2) the association of melanocytic nevus and melanoma is more easily
demonstrated in thinner tumors; and 3) acquired pattern nevi, congenital pattern nevi, and dysplastic nevi are all potential
precursors of melanoma. J Invest Dermatol 100:322S–325S, 1993
The association of melanocytic nevi and melanoma has been an area of
recent interest, initiated largely by the description in 1978 of melanoma
arising in ‘‘heritable melanocytic lesions’’ (now called dysplastic nevi) by
Clark et al [1]. Earlier reports could be found of the association of
melanoma and moles, especially in families [2,3]. This association had
even been noted in the 1800s; however, the observation of dysplastic
nevi and the description of the dysplastic nevus syndrome [4] focused
attention on these lesions as potential precursors of melanoma and as
markers of increased risk of developing melanoma. It was hoped that the
ability to identify risk groups for the development of melanoma [5–10] –
including those people with dysplastic, acquired, and/or congenital
melanocytic nevi –would allow earlier diagnosis and improved survival,
a hope only partially fulfilled.
Nevi are present in the majority of light-skinned people but are more
common in patients with melanoma than in control subjects [7–10]. In a
review of multiple reported series, Elder et al [11] found that patients with
cutaneous melanoma gave a history of a pre-existing clinical pigmented
lesion at a melanoma site in 18–85% of primary melanoma cases. Such a
range is of little use to either the educated patient or the patient’s
physician in trying to determine which mole, if any, should be
considered a potential precursor lesion. It is difficult to know whether
the history from a patient of a pre-existing pigmented lesion represents
early melanoma or a benign nevus. From the demonstrated difficulty of
accurate clinical diagnosis of melanocytic lesions [12], it would seem
that the appearance alone is not uniformly helpful. Some patients report a
definite stable lesion undergoing a more or less recent change [13], and
such an accurate history may well be related to malignant transformation
in precursor nevi. The history of a pigmented lesion present since birth at
the site of a melanoma seems somewhat more accurate, especially when
confirmed by photographs or questioning of parents [14,15]. Now that
dysplastic nevi have become a focus of attention for evaluating precursor
lesions, a consensus of clinical and histologic definition is needed.
Studies of combined clinical and histologic features seem to allow a
more accurate diagnosis of dysplastic nevi [16]. In part because of the
lack of uniformity of definition, however, the reports of histologic
melanocytic dysplasia in association with melanoma range from 5 to
36% [11,17–20].
In addition to clinical judgment of either patient or physician, the
histologic presence of benign nevus cells, whether dysplastic or not,
as a distinct population separate from the melanoma cells can also be
used to assess the association of melanocytic nevi and melanoma. The
purpose of the present study was 1) to determine in a large referral
melanoma clinic the incidence of various types of histologic melanocytic
nevi in association with primary cutaneous melanoma, and 2) to test
whether tumor thickness had any bearing on the ability to assess the
presence of nevi.
MATERIALS AND METHODS
Data Base The computerized data base of the Melanoma Clinic at
the University of California, San Francisco, was searched for patients
with malignant melanoma, superficial spreading (SSM) and nodular
(NM) types who also had information concerning the presence or
absence of an associated benign melanocytic nevus. A subset of the
data was searched for type of nevus.
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The Melanoma Clinic has entered clinical and histologic data
prospectively since March 1971. A total of 3450 patients have been
seen with all types of melanoma at all stages of the disease. After
excluding unusual types, unknown primaries, and 206 patients whose
pathology was inadequate for evaluation, there remained a population
of 1954 patients with SSM and NM who also had adequate histologic
material for evaluation of pre-existing nevi. In the data base, tumor
thickness was measured by the Breslow technique [21].
Definitions
Tumor Type: Histogenetic types SSM/NM were classified in routine
hematoxylin and eosin-stained sections using the original descrip-
tion of Clark et al in 1969 [22]. Other types, such as lentigo
maligna, acral lentiginous melanoma, and unclassified or unusual
types, were excluded from this analysis because preliminary studies
indicated that types other than SSM/NM had such a low prevalence
that no analysis of data could be made with regard to these types.
Associated Nevus: The dermal component of a melanocytic nevus had
to appear as a cell type distinct from the melanoma cells to be
recorded. To avoid confusion in differentiating in situ melanoma from
junctional nevus, the junctional component was only considered in
dysplastic nevi. The dermal nevus was recognized by smaller size,
absent mitoses, orderly pattern of growth, and lack of lymphocytic or
mesenchymal (vascular and/or stromal) host response. Melanomas in
which larger tumor cells gradually diminished in size at the base were
not included because the distinction between two cell types, as noted
above, could not be made.
Nevus Type:Whenever possible, the associated nevus was classified as
acquired pattern, congenital pattern, or dysplastic, using the following
definitions [23]: 1) The acquired pattern is present within the epidermis
and/or the expanded papillary dermis. It is orderly and confined
laterally as well as at the deep margin along the papillary-reticular
dermal junction. 2) The congenital pattern nevus extends between
reticular dermal collagen bundles and is closely associated with
appendages, especially pilosebaceous units. As used in this study,
nevus cells do not need to descend into the lower third of the reticular
dermis, as suggested by Mark et al [24], if they exhibit the above
criteria. This is a histologic pattern, not necessarily correlated with the
clinical definition of ‘‘apparent at birth,’’ as discussed by Rhodes
[13,14]. 3) The dysplastic nevus, although considered ill defined by
many and nonexistent by a few [26], is nevertheless not difficult to
define. The generally accepted published criteria were followed
[9,16,18,20,23,27,28]. These include lateral extension of an intraepi-
dermal melanocytic proliferation beyond a dermal nevus; disordered
architecture of the epidermis; a cellular-mesenchymal host response,
including angiogenesis, fibroplasia, and cross-bridging of adjacent rete
ridges, and the presence of atypical individual melanocytes in the
epidermis. Because of the characteristic pattern of epidermal ridge
pattern and junctional nest cross-bridging in dysplastic nevi, the
junctional changes were considered an integral part of the diagnosis.
RESULTS
Incidence of Associated Nevi In the overall population of 1954 cases of
SSM/NM, 1126 showed histologic evidence of an associated benign
melanocytic nevus (57.6%).
Incidence by Tumor Thickness When the population was stratified by
tumor thickness, the numbers of associated nevi decreased as the tumor
thickness increased: 64.9% of tumors less than 0.76mm and 64.5% of
those between 0.76 and 1.69mm contained associated nevi, whereas in
the thickness range 1.70–3.60mm, there were 45.6% associated nevi
(Table I). In melanomas greater than 3.60mm, only 32.0% were found to
have associated dermal melanocytic nevus cells.
Incidence by Type of Nevus and Tumor A subset of 808 patients
from the above population had data entered on both histogenetic type
and, in more recent years, nevus subtype (Table II). There were 714
tumors of the SSM type, which were analyzed. By the preceding
definitions of melanocytic nevus, 42% of the SSM type were associ-
ated with acquired pattern nevi, 35% were found to have a congenital
pattern nevus, and 24% were associated with a nevus showing features
of dysplasia.
Of the 94NM tumors, 38% were associated with acquired pattern
nevi, 60% with congenital pattern nevi, and only 2% with dysplastic
nevi. Of the total 808 SSM and NM tumors classified in this way, 41%
were found to have an associated acquired pattern nevus and 38% an
associated congenital pattern nevus. Dysplastic nevi were found in 21%
of this population.
DISCUSSION
Presence of Associated Nevi in SSM and NM The present study reports
the association of melanocytic nevi found in contiguity with primary
cutaneous malignant melanoma. It is based on a series of prospectively
entered data on patients whose histologic attributes included an
assessment of the presence or absence of an associated melanocytic
nevus. Histologic dermal nevus associated with the melanoma was
found in 57.6% of 1954 patients with primary cutaneous malignant
melanomas. This figure is high when compared with the results of
others (reviewed by Elder et al [11]). Several possible explanations could
be cited:
Table I. Numbers of Melanoma Cases Associated with
Dermal Melanocytic Nevi as a Function of Tumor
Thickness
Tumor Thickness
(mm)a
Total Cases of
Melanomab
Cases Associated with
Nevus (%)
o0.76 696 452 (64.9)
0.76–1.69 659 425 (64.5)
1.70–3.60 421 192 (45.6)
43.60 178 57 (32.0)
Total 1954 1126 (57.6)
aMillimeters by ocular microscopic on slide.
bSSM and NM types only.
Table II. Correlation of Melanocytic Nevus Type
Associated with Histogenetic Types of Melanoma
Nevus Type SSM (%) NM (%) Total (%)
Acquired 298 (42) 36 (38) 333 (41)
Congenital 248 (35) 56 (60) 304 (38)
Dysplastic 168 (24) 2 (2) 171 (21)
Total 714 94 808
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1. The present study included only SSM/NM, and perhaps these
have the highest association with precursor nevi. It is difficult to
assume that the restriction of the present study to the SSM/NM
types of melanoma could alone account for this difference
because these histogenetic types account for 85–90% of most
large series of malignant melanoma. Other types, such as acral
lentiginous melanoma or those arising in lentigo maligna, were
seldom found associated with nevi in a preliminary search of
the data base, and they would only account for a maximum
10–15% dilution. Marks et al [29] also studied only SSM and
NM tumors and found that 23.3% of cases had an associated
melanocytic nevus. This study, however, utilized 12 patho-
logists in the Dorevitch Pathology Laboratory in Melbourne,
Australia. The authors did not state specifically their criteria for
the diagnosis of nevus or whether they included both junctional
and dermal components.
2. The diagnostic criteria were not similar to those used in other
studies. Friedman et al [30], who studied 557 patients with
primary malignant melanoma, specifically excluded ‘‘melano-
mas associated with histologic evidence of congenital as
opposed to acquired melanocytic nevi’’; they also found that
23% of their series had histologic evidence of an acquired
melanocytic nevus in association with the melanoma. They cite
similar criteria to those used in the present study.
3. The criteria were not applied consistently in these lesions. In an
earlier study using the same criteria and the same pathologist
[31], it was shown that 50% of in situ and 53% of thin
melanomas less than 0.76mm were associated with precursor
nevi. This suggests that the populations and the pathologist are
similar over time but does not explain the lower figures reported
by others.
4. The population studied differed in some way from others
reporting lower figures. It is possible that the study population
comprises a higher proportion of patients with so-called low-
risk or thin tumors than other series. It can be seen from Table I
that more than one-third of the patients (696 of 954, or 35.6%)
had tumors less than 0.76mm thick and that more than two-
thirds had tumors less than 1.70mm thick. In thinner tumors it
seems reasonable to as sume that the residua of associated nevi
would be more apparent than in more deeply invasive tumors.
Incidence by Tumor Thickness The results indicate a clear decrease in
the numbers of associated dermal nevi in contiguity with primary
melanoma of increasing tumor thickness. As indicated above, there were
a large number of thin tumors in the overall data base, and 65% of those
tumors less than 1.70mm showed associated nevi. In the study by Marks
et al [29], the frequency of melanoma-associated nevi was found to
decrease with level of invasion from 31.3% of level I tumors to 21.3% of
level IV tumors. Thickness was only analyzed as less than or greater than
1.0mm, but in this division the percent of associated nevi was 27.0 and
14.8%, respectively. Although the trend toward fewer nevi demonstrable
in thicker or deeper tumors can be seen in the study by Marks et al, the
absolute numbers are lower, as noted above. In fact, Marks et al
concluded that most melanomas do not arise in pre-existing nevi,
whereas the present study supports the suggestion that most thin
melanomas do in fact arise in association with pre-existing nevi. Whether
the thicker tumors develop with a similar proportion of nevi and the
tumor growth over-rides the nevus, or whether thicker tumors develop
less frequently in nevi and attain a greater thickness because of some
other mechanism, is not known.
The contribution of Friedman et al [30] suggests a more favorable
prognosis in those melanomas associated with acquired melanocytic
nevi. Confirmation of this study by another group is lacking, and the
present study did not address this issue.
Incidence of Nevus Type and Histogenetic Type In SSM associated with
nevi, 42% are of the acquired type; 35% are congenital nevi, and 24%
show features of dysplasia. It must be remembered that these data include
all tumor thicknesses, so that the congenital pattern nevus may be
somewhat over-represented in thicker tumors because its nevus cells
extend deeper, and it would take a thicker tumor to obscure the nevus.
The finding of dysplastic nevi in almost one-quarter of SSM is also high
compared with other published studies but can perhaps be explained on
the basis of the referral pattern of patients who have unusual mole
patterns and the increased likelihood of detecting thin tumors in this
subgroup. The findings of Hastrup et al [18], showing approximately 7%
of melanoma arising in a prior dysplastic nevus, are based on a
population-based study and are probably closer to the actual incidence.
In the case of NM, 38% were associated with acquired pattern nevi
and 60% were associated with congenital pattern nevi. It must be
remembered that thickness is not included in this analysis, so that NM
developing in contiguity with acquired nevi could quickly obscure or
destroy the precursor nevus. Because the acquired pattern was defined as
confined to the papillary dermis, one might not expect many NM tumors
to remain confined to this anatomic site because the vertical growth of
such tumors fills the papillary dermis even in thin NM tumors. A deeper
nevus, as defined by the congenital pattern, could be seen more easily in
association with the deeper NM tumors. An alternative hypothesis might
be that congenital pattern nevi are truly more prone to develop NM than
other types.
Only two cases (2%) of NM were found to be associated with
dysplastic nevi. This might be expected, considering the fact that the
dysplastic changes are noted at the periphery of the precursor nevus and
that NM is confined to the vertical growth without adjacent spread.
Lateral features would be expected more commonly in melanomas with a
radial growth phase. An alternative explanation for the low prevalence of
dysplastic nevi in association with NM could be misclassification of
dysplastic changes adjacent to the vertical growth as radial growth of
SSM rather than dysplasia in association with NM.
Cook and Robertson [32] examined melanocytic dysplasia and melano-
ma, distinguishing between lentiginous and epithelioid dysplasia. They
concluded that these processes were similar components of a spectrum of
melanocytic dysplasia. They reported that 27.4% of 226 melanomas showed
such changes, a figure similar to the present study. The present study did not
address the issue of separating lentiginous from epithelioid dysplasia.
Finally, the study of Black [17] examined 500 SSM excisions and
found residual remnants of dysplastic nevi in 32.4% of tumors. Although
this is somewhat higher than the present study, which found 24% of SSM
excisions associated with dysplastic nevi, Black also found only 9.8% of
nevi in SSM excisions without dysplasia (compared with 42% of SSM in
the present study).
In conclusion, the present study has shown that melanocytic nevi are
a common association in routine histologic sections of primary
cutaneous malignant melanoma of the SSM and NM types. The overall
frequency of 57.6% of these tumors associated with nevi may be
somewhat elevated by the proportion of thin tumors in this series, but the
frequency of almost two-thirds of melanoma with thicknesses less than
1.70mm associated with dermal nevi indicates that the majority of
melanomas may be associated with precursor nevi. These findings
support the hypothesis of tumor progression in the melanocytic system,
as discussed by Clark [33].
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